Alexis Rugamba

Alexis Rugamba

Auto-generated profile, based on publicly available information

Alexis Rugamba

Department of Microbiology and Parasitology, School of Medicine and Pharmacy, University of Rwanda, KK 737 Street, Gikondo, Kigali, Rwanda

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in JMIR Formative Research
Verified
Journal Article
Open access
DMDjibril Mbarushimana
Djibril Mbarushimana
TATaofeek Adegboyega
Taofeek Adegboyega
GDGatera Jean Damascene
Gatera Jean Damascene
MBMuritala Issa Bale
Muritala Issa Bale
BDBuregeya Jean Damascene
Buregeya Jean Damascene
NCNgarambe Christian
Ngarambe Christian
Background: Antimicrobial resistance (AMR) poses a significant global health threat, requiring effective antimicrobial susceptibility testing (AST) and surveillance systems. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified critical gaps in the Laboratory Information System (LIS), including low capture rates for culture observation (60%) and AST data (25%), no standardization of AST panels (0%), and limited cumulative antibiogram generation (17%). Existing AMR surveillance platforms, such as the Information System for Monitoring Antimicrobial Resistance by the World Health Organization (WHO) Collaborating Center for Surveillance of Resistance to Antimicrobial Agents (WHONET), and the District Health Information System, operate as standalone systems separate from clinical workflows, which limits their real-time clinical utility. Objective: This study aimed to develop an enhanced, web-based LIS integrated within routine clinical care to improve AST reliability, enable real-time AMR surveillance at CHUB, and provide a scalable model for subnational and national surveillance networks in resource-limited settings, supporting antimicrobial stewardship. Methods: We developed an enhanced LIS using the OpenClinic GA, the current open-source hospital information system at CHUB, integrating Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, and leveraging metadata from the AMR for R package, WHONET resources, and EUCAST Expert Rules. An agile development approach was used, incorporating a custom database schema, Java-based application programming interfaces (APIs), and web-based user interfaces. The system was designed to support minimum inhibitory concentration (MIC) and disk diffusion (DD) methods, automate result interpretation with color-coded outputs, WHO Access, Watch, Reserve (AWaRe)–based cascade reporting, and enable data export to WHONET for global surveillance. Results: The enhanced LIS improved AST data capture and standardization, providing reliable, automated result interpretation and real-time AMR surveillance capabilities. The system’s web-based architecture enables scalability through centralized deployment, allowing multiple facilities simultaneous access. Unlike standalone surveillance tools, the enhanced LIS integrates AST within electronic medical records, maintaining clinical information continuity from specimen registration through result reporting. The system supports immediate clinical decision through AWaRe–based cascade reporting, and automated resistance phenotype detection, followed by standardized WHONET-compatible exports for public health surveillance. Conclusions: This scalable, LIS model demonstrates the feasibility of implementing standards-based AMR informatics in resource-limited settings. By embedding surveillance within clinical workflows rather than treating it as a separate downstream activity, the system maximizes data quality and clinical relevance while minimizing staff burden. The centralized web-based architecture provides inherent scalability from facility to national levels, eliminating data fragmentation and ensuring metadata consistency across networks. Long-term sustainability requires continuous user training, designated personnel for metadata maintenance, local IT capacity building, and funding mechanisms beyond donor dependency. This model provides a practical roadmap for national digital stewardship programs, supporting both immediate patient care and long-term public health surveillance goals.

5 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
YBYvan Butera
Yvan Butera
LMLeon Mutesa
Leon Mutesa
EPEdyth Parker
Edyth Parker
RMRaissa Muvunyi
Raissa Muvunyi
EUEsperance Umumararungu
Esperance Umumararungu
Claude Mambo MuvunyiClaude Mambo Muvunyi
Claude Mambo Muvunyi
The ongoing outbreak of Marburg virus disease (MVD) in Rwanda marks the third largest historically, though it has exhibited the lowest fatality rate. Genomic analysis has identified a lineage with limited internal diversity most closely related to a genome sequence from a sporadic case sampled in 2014 in Uganda, though the lineages have diverged from a common ancestor that was circulating for decades in the animal reservoir. Notably, the data also provide evidence that the outbreak resulted from a single zoonotic transmission event with limited human-to-human transmission, rather than multiple independent zoonotic transmission events. The Rwandan MVD outbreak prompted a thorough investigation that included contact tracing, clinical assessment, travel history, sequencing, and serology testing, to trace the virus’s origin. Results of investigations linked the index case to a mining cave inhabited by Rousettus aegyptiacus (the Egyptian fruit bat), where three individuals tested seropositive for IgG and IgM, further supporting the zoonotic origin of the outbreak through human-animal interactions.

25 August 2022 in Epigenomics
Verified
Journal Article
Closed access
CMClarisse Musanabaganwa
Clarisse Musanabaganwa
SJStefan Jansen
Stefan Jansen
AWAgaz Wani
Agaz Wani
ARAlex Rugamba
Alex Rugamba
JMJean Mutabaruka
Jean Mutabaruka
LMLeon Mutesa
Leon Mutesa
Epigenomic and neurocognitive studies have provided new perspectives on post-traumatic stress disorder and its intergenerational transmission. This article outlines the lessons learned from communi... Plain language summary Studies of how human genes are affected by the environment (epigenomic studies) have provided new perspectives on post-traumatic stress disorder and its intergenerational tra...

10 September 2026 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Closed access
PDF file
ARAlexis Rugamba
Alexis Rugamba
PMPernilla Malmgren
Pernilla Malmgren
EBEmile NA BIENVENU
Emile NA BIENVENU
SBSofia Birgersson
Sofia Birgersson
Introduction: Differences in genotypes encoding drug-metabolizing enzymes can lead to variability in both drug response and toxicity. These genotypes vary across geographical regions and ethnic groups, especially in African populations. In general, African populations are underrepresented in clinical trials. This study aimed to determine the allele frequencies of CYP2C8, CYP2C9, CYP2C19, and CYP1B1 in the Rwandan population; to explore potential clinical impact on toxicity of the CYP2C8*2 variant on paclitaxel metabolism and the need for genotype-based dosing using a population pharmacokinetic model. Methods: Genotyping was performed on DNA extracted from blood samples obtained from 82 Rwandan patients. Paclitaxel plasma concentrations for the different CYP2C8 genotypes were simulated based on available in vitro metabolism data and a population pharmacokinetic model. Toxicity was assessed as time above plasma concentration thresholds (>0.05 and 0.1 μM), and genotype-based dose regimens were simulated. Results: The frequencies of the polymorphic alleles in the Rwandan population were 21%, 0.6%, 1.8%, 24%, and 26% for CYP2C8*2, CYP2C9*2, CYP2C19*3, CYP2C19*17, and CYP1B1, respectively. Simulations showed that CYP2C8*2 carriers spent approximately 1.7-fold and 1.9-fold longer above paclitaxel toxicity thresholds of 0.05 and 0.1 μM, respectively, than wild-type individuals. A dose of 100 mg/m² in CYP2C8*2 carriers produced exposure comparable to 175 mg/m² in wild-type individuals. Discussion: The relatively high prevalence of CYP2C8*2 in the Rwandan population suggests potential clinical relevance for paclitaxel treatment. Conclusion: CYP2C8*2 may influence paclitaxel exposure and support genotype-guided dose reduction to improve treatment safety.

24 May 2026 in JMIR Preprints
Verified
Preprint
Open access
DMDjibril Mbarushimana
Djibril Mbarushimana
TATaofeek Adegboyega
Taofeek Adegboyega
GDGatera Jean Damascene
Gatera Jean Damascene
MBMuritala Issa Bale
Muritala Issa Bale
BDBuregeya Jean Damascene
Buregeya Jean Damascene
CNChristian Ngarambe
Christian Ngarambe
BACKGROUND Antimicrobial resistance (AMR) is a global health emergency, disproportionately impacting sub-Saharan Africa where fragmented laboratory information systems (LIS) and inconsistent antimicrobial susceptibility testing (AST) practices limit both clinical decision-making and surveillance capacity. At the University Teaching Hospital of Butare (CHUB) in Rwanda, a baseline Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) identified systemic gaps, including 0% AST panel standardization, 17% cumulative antibiogram generation capacity, and no enforcement of testing quality rules. A standards-based digital infrastructure integrating CLSI- and EUCAST-compliant AST panels into OpenClinic GA with bidirectional WHONet export was implemented in 2024. The implementing study expressly deferred quantitative key performance indicator (KPI) evaluation to allow sufficient post-implementation observation time. OBJECTIVE To quantify the impact of the implemented infrastructure on five KPI domains: (1) AST data capture volume and specimen throughput; (2) data standardization and ease of analysis; (3) laboratory turnaround time (TAT); (4) testing quality, including detection and resolution of specimen-antibiotic incompatibilities, method violations, and intrinsic resistance violations; and (5) antimicrobial resistance (AMR) profiles, including appropriate use of screener discs. METHODS A retrospective pre-post study compared Q1 2024 (pre-implementation; n=505 culture-positive specimens, legacy LIS export) with Q1 2026 (post-implementation; n=3,669 specimens, WHONet-format export) at CHUB. Outcomes included specimen throughput, nomenclature and data structure standardization, TAT (specimen receipt to results release, days), testing quality flags (Nitrofurantoin/Nalidixic acid on non-urine specimens; vancomycin by disc diffusion on staphylococci; ampicillin on intrinsically resistant Enterobacteriaceae), screener disc utilization (Pefloxacin, Cefoxitin), and resistance rates for key pathogens against CLSI 2024 breakpoints. RESULTS Specimen throughput increased 7.3-fold (+626%). Unique organism names decreased from 76 to 39 (-49%), with 11 non-standard spellings of Escherichia coli alone pre-implementation reduced to one WHO-standard entry. All 7,465 post-implementation records carried CLSI 2024 annotations versus 0% pre-implementation. Critical data-analysis fields, age categories, department, TAT timestamps, WHONET antibiotic codes, absent pre-implementation were fully present post-implementation. Pre-implementation errors included: 6 instances of Nitrofurantoin or Nalidixic acid on non-urine specimens, 4 instances of ampicillin on intrinsically resistant Enterobacteriaceae (including 1 spurious susceptible result), and 44 vancomycin results by disc diffusion on staphylococci and streptococci (16 on Staphylococcus aureus), an unreliable method per CLSI. All resolved to zero post-implementation. Screener disc use was transformed: Pefloxacin (fluoroquinolone surrogate for Enterobacteriaceae) was absent pre-implementation and introduced in 95 tests post-implementation; Cefoxitin (MRSA surrogate) was used without a systematic inferential framework pre-implementation (n=81, no inferential display) and formalised under the screener protocol post-implementation (n=33, MRSA rate 24.2%). Median TAT from specimen receipt to results release was 2.80 days (IQR 2.03-3.77). Among key pathogens, Escherichia coli ciprofloxacin resistance was 54.2% and ceftriaxone resistance 42.2%, while carbapenem susceptibility was preserved (imipenem resistance 1.5%). CONCLUSIONS Implementation of a CLSI/EUCAST-compliant digital AST and surveillance infrastructure at CHUB produced measurable, clinically meaningful improvements across all five KPI domains, yielding CHUB's first institution-wide cumulative antibiogram in GLASS-compatible WHONet format. These results fulfill the deferred quantitative evaluation and provide a replicable evidence base for tertiary institutions across sub-Saharan Africa. INTERNATIONAL REGISTERED REPORT RR2-10.2196/82727